499 related articles for article (PubMed ID: 27609942)
1. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB; Sucher AJ; Hemstreet BA
Ann Pharmacother; 2017 Jan; 51(1):44-53. PubMed ID: 27609942
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
4. Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.
Miller MM
Am J Health Syst Pharm; 2017 Jul; 74(14):1045-1052. PubMed ID: 28687550
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB; Kelley D; Childs-Kean LM
Ann Pharmacother; 2018 Apr; 52(4):352-363. PubMed ID: 29115151
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
Gane EJ; Schwabe C; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CA
Gastroenterology; 2016 Sep; 151(3):448-456.e1. PubMed ID: 27240903
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.
Brieva T; Rivero A; Rivero-Juarez A
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):483-490. PubMed ID: 28165830
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
Curry MP; O'Leary JG; Bzowej N; Muir AJ; Korenblat KM; Fenkel JM; Reddy KR; Lawitz E; Flamm SL; Schiano T; Teperman L; Fontana R; Schiff E; Fried M; Doehle B; An D; McNally J; Osinusi A; Brainard DM; McHutchison JG; Brown RS; Charlton M;
N Engl J Med; 2015 Dec; 373(27):2618-28. PubMed ID: 26569658
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Lawitz E; Reau N; Hinestrosa F; Rabinovitz M; Schiff E; Sheikh A; Younes Z; Herring R; Reddy KR; Tran T; Bennett M; Nahass R; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Pearlman B; Shiffman M; Hawkins T; Curry M; Jacobson I
Gastroenterology; 2016 Nov; 151(5):893-901.e1. PubMed ID: 27486034
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
Everson GT; Towner WJ; Davis MN; Wyles DL; Nahass RG; Thuluvath PJ; Etzkorn K; Hinestrosa F; Tong M; Rabinovitz M; McNally J; Brainard DM; Han L; Doehle B; McHutchison JG; Morgan T; Chung RT; Tran TT
Ann Intern Med; 2015 Dec; 163(11):818-26. PubMed ID: 26551051
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
Takehara T; Sakamoto N; Nishiguchi S; Ikeda F; Tatsumi T; Ueno Y; Yatsuhashi H; Takikawa Y; Kanda T; Sakamoto M; Tamori A; Mita E; Chayama K; Zhang G; De-Oertel S; Dvory-Sobol H; Matsuda T; Stamm LM; Brainard DM; Tanaka Y; Kurosaki M
J Gastroenterol; 2019 Jan; 54(1):87-95. PubMed ID: 30203225
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
Izumi N; Takehara T; Chayama K; Yatsuhashi H; Takaguchi K; Ide T; Kurosaki M; Ueno Y; Toyoda H; Kakizaki S; Tanaka Y; Kawakami Y; Enomoto H; Ikeda F; Jiang D; De-Oertel S; McNabb BL; Camus G; Stamm LM; Brainard DM; McHutchison JG; Mochida S; Mizokami M
Hepatol Int; 2018 Jul; 12(4):356-367. PubMed ID: 30030720
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.
Isakov V; Chulanov V; Abdurakhmanov D; Burnevich E; Nurmukhametova E; Kozhevnikova G; Gankina N; Zhuravel S; Romanova S; Hyland RH; Lu S; Svarovskaia ES; McNally J; Brainard DM; Ivashkin V; Morozov V; Bakulin I; Lagging M; Zhdanov K; Weiland O
Infect Dis (Lond); 2019 Feb; 51(2):131-139. PubMed ID: 30499360
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection.
Nehra V; Rizza SA; Temesgen Z
Drugs Today (Barc); 2017 Mar; 53(3):177-189. PubMed ID: 28447075
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
Gane EJ; Kowdley KV; Pound D; Stedman CA; Davis M; Etzkorn K; Gordon SC; Bernstein D; Everson G; Rodriguez-Torres M; Tsai N; Khalid O; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Tong M; Chung RT; Beavers K; Poulos JE; Kwo PY; Nguyen MH
Gastroenterology; 2016 Nov; 151(5):902-909. PubMed ID: 27486033
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.
Greig SL
Drugs; 2016 Oct; 76(16):1567-1578. PubMed ID: 27730529
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
Foster GR; Afdhal N; Roberts SK; Bräu N; Gane EJ; Pianko S; Lawitz E; Thompson A; Shiffman ML; Cooper C; Towner WJ; Conway B; Ruane P; Bourlière M; Asselah T; Berg T; Zeuzem S; Rosenberg W; Agarwal K; Stedman CA; Mo H; Dvory-Sobol H; Han L; Wang J; McNally J; Osinusi A; Brainard DM; McHutchison JG; Mazzotta F; Tran TT; Gordon SC; Patel K; Reau N; Mangia A; Sulkowski M; ;
N Engl J Med; 2015 Dec; 373(27):2608-17. PubMed ID: 26575258
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.
Jonas MM; Romero R; Rosenthal P; Lin CH; Verucchi G; Wen J; Balistreri WF; Whitworth S; Bansal S; Leung DH; Narkewicz MR; Gonzalez-Peralta RP; Mangia A; Karnsakul W; Rao GS; Shao J; de Jong J; Parhy B; Osinusi A; Kersey K; Murray KF; Sokal EM; Schwarz KB
J Pediatr Gastroenterol Nutr; 2024 Jun; 78(6):1342-1354. PubMed ID: 38644678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
